Antimetastatic activities of pegylated liposomal doxorubicin in a murine metastatic lung cancer model

References

• A Alexopoulos, MV Karamouzis, H Stavirinides, A Ardavanis, K Kandilis, J Stavrakakis, C Georganta, and G Rigatos. 2004. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 15:891–895.
   PubMed Web of Science ®Google Scholar
• TM Allen, and PR Cullis. 2004. Drug delivery system: Entering the mainstream. Science 303:1818–1822.
   PubMed Web of Science ®Google Scholar
• TM Allen, CB Hansen, and DE Lopes de Menezes. 1995. Pharmacokinetics of long-circulating liposomes. Adv Drug Del Rev 16:267–284.
   Web of Science ®Google Scholar
• GR Bartlett. 1959. Phosphorus assay in column chromatography. J Biol Chem 234:466–468.
   PubMed Web of Science ®Google Scholar
• G Bocci, KC Nicolaou, and RS Kerbel. 2002. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62:6938–6943.
   PubMed Web of Science ®Google Scholar
• A Cabanes, D Tzemach, D Geren, AT Horowitz, and A Gabizon. 1998. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 4:499–505.
   PubMed Web of Science ®Google Scholar
• S Chan, N Davidson, E Juozaityte, F Erdkamp, A Pluzanska, N Azarnia, and LW Lee. 2004. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 15:1527–1534.
   PubMed Web of Science ®Google Scholar
• T Chao, W Wang, C Yen, T Chiou, J Liu, and P Chen. 2003. A dose-escalating pilot study of sterically stabilized, pegylated liposomal doxorubicin (Lipo-Dox) in patients with metastatic breast cancer. Cancer Invest 21:837–847.
   PubMed Web of Science ®Google Scholar
• GT Colbern, AJ Hiller, RS Musterer, E Pegg, C Henderson, and PK Working. 1999. Significant increase in antitumor potency of doxorubicin HCl by its encapsulation in pegylated liposomes. J Liposome Res 9:523–538.
   Web of Science ®Google Scholar
• DC Drummond, O Meyer, K Hong, DB Kirpotin, and D Papahadjopoulos. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691–743.
   PubMed Web of Science ®Google Scholar
• AA Gabizon. 2001. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19:424–436.
   PubMed Web of Science ®Google Scholar
• AA Gabizon, Y Barenholz, and M Bialer. 1993. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. Pharm Res 10:703–708.
   PubMed Web of Science ®Google Scholar
• E Gorelik, S Segel, and M Feldman. 1980. Control of lung metastasis progression in mice: Role of growth kinetics of 3LL Lewis lung carcinoma and host immune activity. J Natl Cancer Inst 65:1257–1264.
   PubMed Web of Science ®Google Scholar
• G Haran, R Cohen, LK Bar, and Barenholz. 1993. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151:201–215.
   PubMed Web of Science ®Google Scholar
• RS Kerbel, G Klement, KI Pritchard, and B Kamen. 2002. Continuous low-dose anti-angiogenic/metronomic chemotherapy: From the research laboratory into the oncology clinic. Ann Oncol 13:12–15.
   PubMed Web of Science ®Google Scholar
• Y Kimura, and M Sumiyoshi. 2005. Antitumor and antimetastatic actions of eicocapentaenoic acid ethylester and its by-products formed during accelerated stability testing. Cancer Sci 96:441–450.
   PubMed Web of Science ®Google Scholar
• NV Koshkina, ES Kleinerman, C Waldrep, SF Jia, LL Worth, BE Gilbert, and V Knight. 2000. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6:2876–2880.
   PubMed Web of Science ®Google Scholar
• NV Koshkina, JC Waldrep, LE Roberts, E Golunski, S Melton, and V Knight. 2001. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 7:3258–3262.
   PubMed Web of Science ®Google Scholar
• K Krishnan, C Khanna, and LJ Helman. 2006. The molecular biology of pulmonary metastasis. Thorac Surg Clin 16:115–124.
   PubMedGoogle Scholar
• O Lyass, B Uziely, R Ben-Yosef, D Tzemach, NI Heshing, M Lotem, G Brufman, and A Gabizon. 2000. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037–1047.
   PubMed Web of Science ®Google Scholar
• EH Moase, W Qi, T Ishida, Z Gabos, BM Longenecker, GL Zimmermann, L Ding, M Krantz, and TM Allen. 2001. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophy Acta 1510:43–55.
   PubMed Web of Science ®Google Scholar
• E Mrozek, CA Rhoades, J Allen, EM Hade, and CL Shapiro. 2005. Phase I trial of liposomal encapsulated doxorubicin (MyocetTM; D-99) and weekly docetaxel in advanced breast cancer patients. Ann Oncol 16:1087–1093.
   PubMed Web of Science ®Google Scholar
• F Muggia. 2003. Doxorubicin for metastatic breast cancer: Time for a change?. Cancer Invest 21:967–968.
   PubMed Web of Science ®Google Scholar
• JC Murray, and SM Moghimi. 2003. Endothelial cells as therapeutic targets in cancer: New biology and novel delivery system. Crit Rev Ther Drug Carrier Syst 20:139–152.
   PubMed Web of Science ®Google Scholar
• TH Nguyen. 2004. Mechanisms of metastasis. Clin Dermatol 22:209–216.
   PubMed Web of Science ®Google Scholar
• D Papahadjopoulos, TM Allen, A Gabizon, E Mayhew, K Matthay, SK Huang, KD Lee, MC Woodle, DD Lasic, C Redemann, and FJ Martin. 1991. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 88:11460–11464.
   PubMed Web of Science ®Google Scholar
• MJ Parr, SM Ansell, LS Choi, and PR Cullis. 1994. Factors influencing the retention and chemical stability of poly(ethylene glycol)–lipid conjugates incorporated into large unilamellar vesicles. Biochim Biophys Acta 1195:21–30.
   PubMed Web of Science ®Google Scholar
• F Pastorino, C Brignole, D Marimpietri, M Cilli, C Gambini, D Ribatti, R Longhi, TM Allen, A Corti, and M Ponzoni. 2003. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63:7400–7409.
   PubMed Web of Science ®Google Scholar
• E Rivera, V Valero, B Arun, M Royce, R Adinin, K Hoelzer, R Walters, JL Wade, L Pusztai, and GN Hortobagyi. 2003. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21:3249–3254.
   PubMed Web of Science ®Google Scholar
• T Sakakibara, F Chen, H Kida, K Kunieda, RE Cuenca, FJ Martin, and RB Bankert. 1996. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing convertional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res 56:3743–3746.
   PubMed Web of Science ®Google Scholar
• H Song, J Zhang, Z Han, X Zhang, Z Li, L Zhang, M Fu, C Lin, and J Ma. 2006. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin. Cancer Chemother Pharmacol 57:591–598.
   PubMed Web of Science ®Google Scholar
• R Straubinger, RD Arnold, R Zhou, R Mazurchuk, and JE Slack. 2004. Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res 24:397–404.
   PubMed Web of Science ®Google Scholar
• S Strieth, ME Eichhorn, B Sauer, B Schulze, M Teifel, U Michaelis, and M Dellian. 2004. Neovascular targeting chemotherapy: Encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 110:117–124.
   PubMed Web of Science ®Google Scholar
• VP Torchilin. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145–160.
   PubMed Web of Science ®Google Scholar
• J Vaage, E Mayhew, D Lasic, and F Martin. 1992. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer 51:942–948.
   PubMed Web of Science ®Google Scholar
• J Vaage, D Donovan, T Loftus, and P Working. 1995. Prevention of metastasis from mouse mammary carcinomas with liposomes carrying doxorubicin. Br J Cancer 72:1074–1075.
   PubMed Web of Science ®Google Scholar
• KY Yoneda, S Louie, and DK Shelton. 2000. Approach to pulmonary metastases. Curr Opin Pulm Med 6:356–363.
   PubMedGoogle Scholar
• R Zhou, R Mazurchuk, and RM Straubinger. 2002. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res 62:2561–2566.
   PubMed Web of Science ®Google Scholar